Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor Promoting Microenvironment
Min Lü(Central South University), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Lijuan Xia(Icahn School of Medicine at Mount Sinai)
Cited by 4
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484
A genetic mechanism for Tibetan high-altitude adaptation
|Nature Genetics|2014|441